Systemic administration of fluoro-gold for the histological assessment of vascular structure, integrity and damage

Current Neurovascular Research

Volumn 11, Issue 1, 2014, Pages 31-47

  Bowyer, John F ^a   Tranter, Karen M ^b   Sarkar, Sumit ^a   Raymick, James ^b   Hanig, Joseph P ^c   Schmued, Larry C ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b Center for Drug Evaluation and Research/FDA ^*

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Amphetamine; Blood brain barrier; Fluoro Gold; Hemorrhage; Kainate; Vascular elements

Indexed keywords

AMPHETAMINE; ENDOTHELIAL CELL ANTIBODY; FLUOROGOLD; KAINIC ACID; PROPIDIUM IODIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL INJURY; BRAIN BLOOD VESSEL; BRAIN CORTEX; BRAIN PERFUSION; CELL NUCLEUS; CHOROID PLEXUS; CONTROLLED STUDY; CORPUS CALLOSUM; CORPUS STRIATUM; CYTOPLASM; DRUG DOSE INCREASE; ENDOTHELIUM CELL; EXTRACELLULAR SPACE; HIPPOCAMPUS; HISTOLOGY; IMMUNOGOLD LABELING; IMMUNOREACTIVITY; IN VIVO STUDY; ISOTOPE LABELING; MACROPHAGE; MALE; MENINX; MICROGLIA; NONHUMAN; PARIETAL CORTEX; PENETRATING TRAUMA; PRIORITY JOURNAL; PYRIFORM CORTEX; RAT; VASCULAR ENDOTHELIUM;

ANIMALS; BLOOD VESSELS; BRAIN; CALCIUM-BINDING PROTEINS; CELL ADHESION MOLECULES; CHOROID PLEXUS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID AGONISTS; KAINIC ACID; MALE; MICROFILAMENT PROTEINS; PROPIDIUM; RATS; RATS, SPRAGUE-DAWLEY; STATUS EPILEPTICUS; STILBAMIDINES; TIME FACTORS; WOUNDS, PENETRATING;

EID: 84898768904     PISSN: 15672026     EISSN: 18755739     Source Type: Journal    
DOI: 10.2174/1567202610666131124235011     Document Type: Article

References (30)

1. Schmued LC, Fallon JH. Fluoro-Gold: a new fluorescent retrograde axonal tracer with numerous unique properties. Brain Res 1986; 377(1): 147-54.
2. Naumann T, Hartig W, Frotscher M. Retrograde tracing with Fluoro-Gold: different methods of tracer detection at the ultrastructural level and neurodegenerative changes of back-filled neurons in long-term studies. J Neurosci Methods 2000; 103(1): 11-21.
3. Zappone CA, Sloviter RS. Commissurally projecting inhibitory interneurons of the rat hippocampal dentate gyrus: a colocalization study of neuronal markers and the retrograde tracer Fluoro-gold. J Comp Neurol 2001; 441(4): 324-44.
4. Bowyer JF, Gough B, Broening HW, Newport GD, Schmued L. Fluoro-gold and pentamidine inhibit the in vitro and in vivo release of dopamine in the striatum of rat. J Pharmacol Exp Ther 1993; 266(2): 1066-74.
5. Kiyatkin EA, Brown PL, Sharma HS. Brain edema and breakdown of the blood-brain barrier during methamphetamine intoxication: critical role of brain hyperthermia. Eur J Neurosci 2007; 26(5): 1242-53.
6. Hoffmann A, Bredno J, Wendland M, Derugin N, Ohara P, Wintermark M. High and Low Molecular Weight Fluorescein Isothiocyanate (FITC)-Dextrans to Assess Blood-Brain Barrier Disruption: Technical Considerations. Transl Stroke Res 2011; 2(1): 106-11.
7. Chung YC, Kim YS, Bok E, Yune TY, Maeng S, Jin BK. MMP-3 contributes to nigrostriatal dopaminergic neuronal loss, BBB damage, and neuroinflammation in an MPTP mouse model of Parkinson's disease. Mediators Inflamm 2013; 2013: 370526.
8. Zhao C, Ling Z, Newman MB, Bhatia A, Carvey PM. TNF-alpha knockout and minocycline treatment attenuates blood-brain barrier leakage in MPTP-treated mice. Neurobiol Dis 2007; 26(1): 36-46.
9. Sarkar S, Schmued L. In vivo administration of fluorescent dextrans for the specific and sensitive localization of brain vascular pericytes and their characterization in normal and neurotoxin exposed brains. Neurotoxicology 2012; 33(3): 436-43.
10. Bowyer JF, Peterson SL, Rountree RL, Tor-Agbidye J, Wang GJ. Neuronal degeneration in rat forebrain resulting from Damphetamine- induced convulsions is dependent on seizure severity and age. Brain Res 1998; 809(1): 77-90.
11. Hezel M, Ebrahimi F, Koch M, Dehghani F. Propidium iodide staining: a new application in fluorescence microscopy for analysis of cytoarchitecture in adult and developing rodent brain. Micron 2012; 43(10): 1031-8.
12. Bowyer JF, Thomas MT, Schmued LC, Ali SF. Brain regionspecific neurodegenerative profiles showing the relative importance of amphetamine dose, hyperthermia, seizures and the blood-brain barrier. Ann NY Acad Sci 2008; 1139: 127-39.
13. Buening MK, Gibb JW. Influence of methamphetamine and neuroleptic drugs on tyrosine hydroxylase activity. Eur J Pharmacol 1974; 26(1): 30-4.
14. Ellinwood EH, Jr. Escalante O. Behavior and histopathological findings during chronic methedrine intoxication. Biol Psychiatry 1970; 2(1): 27-39.
15. Ricaurte GA, Schuster CR, Seiden LS. Long-term effects of repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain: a regional study. Brain Res 1980; 193(1): 153-63.
16. Seiden LS, Fischman MW, Schuster CR. Long-term methamphetamine induced changes in brain catecholamines in tolerant rhesus monkeys. Drug Alcohol Depend 1976; 1(3): 215-9.
17. Commins DL, Seiden LS. alpha-Methyltyrosine blocks methylamphetamine- induced degeneration in the rat somatosensory cortex. Brain Res 1986; 365(1): 15-20.
18. Sharma HS, Dey PK. Influence of long-term immobilization stress on regional blood-brain barrier permeability, cerebral blood flow and 5-HT level in conscious normotensive young rats. J Neurol Sci 1986; 72(1): 61-76.
19. Christov A, Ottman J, Hamdheydari L, Grammas P. Structural changes in Alzheimer's disease brain microvessels. Curr Alzheim Res 2008; 5(4): 392-5.
20. Kalaria RN, Pax AB. Increased collagen content of cerebral microvessels in Alzheimer's disease. Brain Res 1995; 705(1-2): 349-52.
21. Miyakawa T, Shimoji A, Kuramoto R, Higuchi Y. The relationship between senile plaques and cerebral blood vessels in Alzheimer's disease and senile dementia. Morphological mechanism of senile plaque production. Virchows Arch B Cell Pathol Incl Mol Pathol 1982; 40(2): 121-9.
22. Morgan C, Inestrosa NC. Interactions of laminin with the amyloid beta peptide. Implications for Alzheimer's disease. Braz J Med Biol Res 2001; 34(5): 597-601.
23. Palu E, Liesi P. Differential distribution of laminins in Alzheimer disease and normal human brain tissue. J Neurosci Res 2002; 69(2): 243-56.
24. Ergul A, Kelly-Cobbs A, Abdalla M, Fagan SC. Cerebrovascular complications of diabetes: focus on stroke. Endocr Metab Immune Disord Drug Targets 2012; 12(2): 148-58.
25. Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev 2013; 93(1): 137-88.
26. Huber JD. Diabetes, cognitive function, and the blood-brain barrier. Curr Pharm Des 2008; 14(16): 1594-600.
27. Nelson PT, Smith CD, Abner EA, et al. Human cerebral neuropathology of Type 2 diabetes mellitus. Biochim Biophy Acta 2009; 1792(5): 454-69.
28. Jialal I, Kaur H, Devaraj S, Smith G. Human C-reactive protein induces endothelial dysfunction in biobreeding diabetic rats. Diabetes & vascular disease research. Diab Vasc Dis Res 2013; 10(6): 550-3.
29. Kong LL, Wu H, Cui WP, et al. Advances in murine models of diabetic nephropathy. J Diabeties Res 2013; 2013: 797548.
30. Lupachyk S, Watcho P, Shevalye H, et al. Na+/H+ exchanger 1 inhibition reverses manifestation of peripheral diabetic neuropathy in type 1 diabetic rats. Am J Physiol Endocrinol Metab 2013; 305(3): E396-404.